BioCentury
ARTICLE | Company News

Lilly grants Eddingpharm antibiotic rights in China

November 11, 2016 12:03 AM UTC

Eli Lilly and Co. (NYSE:LLY) granted Eddingpharm Inc. (Shanghai, China) exclusive rights to promote and distribute antibiotics Ceclor cefaclor and Vancocin vancomycin in mainland China, effective Jan. 1, 2017. Lilly spokesperson Teresa Shewman declined to provide financial terms.

Lilly said the deal will enable it to focus resources on its innovative portfolio and pipeline. It plans to introduce 10 new drugs to the China market over the next decade...